Introduction {#s0005}
============

Prostate cancer is a common malignancy and a leading cause of cancer-related deaths. As in many other types of cancers, prostatic carcinogenesis is a multistep process that results from the accumulation of multiple genetic and epigenetic alterations. Identification and functional characterization of the cancer-causing alterations provides important molecular insights into how a cancer forms and improves cancer detection and treatment. While a number of genes have been identified with genetic/epigenetic alterations and causal roles in cancer, more such genes remain to be discovered and functionally examined. Chromosomal deletion is one of the most common genetic alterations in human cancer, and one common consequence of chromosomal deletion is the inactivation of tumor suppressor genes during carcinogenesis [@bb0005]. In prostate cancer, a number of commonly deleted chromosomal regions have been mapped, and one or more tumor suppressor genes have been identified for some of the commonly deleted regions, including phosphatase and tensin homolog (*PTEN*) from 10q22, *NKX3-1* from 8p21, and *ATBF1* from 16q22 [@bb0005], [@bb0010], [@bb0015], [@bb0020]. Key evidence for the tumor suppressor activity of a gene is the induction of neoplastic alteration after its deletion in mice, as seen for a number of tumor suppressor genes including *Pten*, *Nkx3-1*, *p53*, *Rb*, and *Smad4* [@bb0025], [@bb0030], [@bb0035], [@bb0040].

*Krüppel-like factor 5* (*KLF5*, also known as *BTEB2*), encoding a basic transcription factor and located at the q21 band of human chromosome 13 (13q21), centers the second most frequently deleted chromosomal region in human prostate cancer, as revealed by comparative genomic hybridization studies [@bb0005], [@bb0045], [@bb0050]. The deletion is exclusively hemizygous, causing the haploinsufficiency of *KLF5* during cancer development [@bb0050], [@bb0055], [@bb0060]. In addition, KLF5 protein is degraded by the ubiquitin proteasome pathway, and one E3 ubiquitin ligase that degrades KLF5, WWP1, is amplified and overexpressed in human prostate and breast cancers, causing excessive protein degradation and functional insufficiency of KLF5 [@bb0065], [@bb0070], [@bb0075]. These findings indicate that *KLF5* is frequently inactivated during human carcinogenesis and thus could be a tumor suppressor gene, and some functional studies indeed support a tumor suppressor function of KLF5. For example, KLF5 can inhibit the proliferation of epithelial cells including some cancer cell lines in culture [@bb0050], [@bb0055], [@bb0080], [@bb0085] and suppresses the tumorigenesis of human prostate cancer cell lines in nude mice [@bb0090]. However, KLF5 has also been demonstrated to promote the tumorigenesis of a bladder cancer cell line in a xenograft model [@bb0095] and mediate or be necessary for intestinal tumorigenesis induced by other oncogenic events in genetically modified mice [@bb0100], [@bb0105], [@bb0110], [@bb0115]. Our recent study indicates that KLF5 indeed can be both tumor suppressing and tumor promoting in the same cancer cell lines in xenograft models and that the acetylation status of KLF5 determines its function in tumorigenesis [@bb0120]. Nevertheless, whether frequent deletion of *KLF5* in human prostate cancer has any functional consequences remains uncertain, because our previous study demonstrated that, in mouse prostates, hemizygous deletion of *Klf5* alone increases cell proliferation and induces hyperplasia but does not cause neoplastic alterations such as mouse prostatic intraepithelial neoplasia (mPIN) or tumor [@bb0125], and homozygous deletion of *Klf5* causes apoptosis rather than increases cell proliferation and does not induce any noticeable histologic alterations [@bb0125]. Therefore, a tumor suppressor function has not been established for KLF5 using genetically modified mice.

PTEN, a protein and lipid phosphatase that negatively regulates phosphoinositide 3-kinase (PI3K)/AKT oncogenic signaling, is a tumor suppressor that undergoes frequent mutations and deletions in human tumors including prostate cancer [@bb0130]. Activation of PI3K/AKT signaling by PTEN inactivation stimulates cell cycle progression and survival and, consequently, induces tumorigenesis [@bb0135], as demonstrated by the induction of prostate cancer after *Pten* homozygous deletion in mice [@bb0025]. Similar to KLF5, chromosomal deletion is also a common mechanism for the loss of PTEN function in different types of human cancers including prostate cancer [@bb0005], [@bb0130], [@bb0140]. As two of the most commonly deleted genetic loci in human prostate cancer, deletion of both *PTEN* and *KLF5* can occur in the same tumors. For example, the commonly used human prostate cancer cell line LNCaP has the deletion of both *PTEN* and *KLF5* [@bb0050], [@bb0145]. It is thus possible that simultaneous deletions of *KLF5* and *PTEN* cooperate to initiate and promote tumorigenesis.

In this study, we tested whether and how simultaneous deletions of *Klf5* and *Pten* interact to initiate and promote prostatic tumorigenesis in mice. We found that deletion of *Klf5* accelerated the emergence and progression of mPIN induced by hemizygous deletion of *Pten*. In the *Pten*-null background, *Klf5* deletion increased cell proliferation and promoted tumorigenesis, as indicated by more severe morphology. Interestingly, while *Pten* deletion alone increased the ratio of basal to luminal cells in a tumor as previously reported, *Klf5* deletion in the *Pten*-null background increased luminal but diminished basal cell population in tumors. Mechanistically, *Klf5* deletion dysregulated a large number of genes and signaling pathways, including the up-regulation of extracellular growth factor, epidermal growth factor (EGF), and its downstream signaling molecules AKT and extracellular signal-regulated kinases (ERK) and the inhibition of the p15 cell cycle inhibitor. Several transcription factors appear to cooperate with KLF5 to function in the prostate. These findings provide *in vivo* evidence for the tumor suppressor activity of KLF5. They also provide a mouse model of prostate cancer that shares two common genetic alterations with human prostate cancer.

Materials and Methods {#s0010}
=====================

Mouse Strains {#s0025}
-------------

The *Klf5* floxed mouse strain, in which the genomic DNA from exon 2 to exon 3 of *Klf5* is flanked by loxP sites, was generated as described in our previous study [@bb0125]. The PB-Cre4 transgenic mouse strain, where expression of Cre recombinase is driven by the prostatic epithelial specific probasin promoter [@bb0150], was purchased from the NCI Mouse Models of Human Cancers Consortium (MMHCC, Frederick, MD; Cat. No. 01XF5). *Pten* floxed mice were purchased from the Jackson Laboratory (Bar Harbor, ME; Cat. No. 004597). All mice were maintained in a mixed background of C57BL/6 J and 129Sv/J.

Mouse Breeding and Genotyping {#s0030}
-----------------------------

The breeding strategy is shown in [Figure 1](#f0005){ref-type="fig"}*A*. Floxed-Klf5 mice (*Klf5*^flox/flox^) were crossed with floxed-Pten mice (*Pten*^flox/flox^), and the F1 mice were then crossed with PB-Cre4 mice to generate the following six desired genotypes: *Cre^+^/Pten^flox/wt^/Klf5^wt/wt^*, *Cre^+^/Pten^flox/wt^/Klf5^flox/wt^*, *Cre^+^/Pten^flox/wt^/Klf5^flox/flox^*, *Cre^+^/Pten^flox/flox^/Klf5^wt/wt^*, *Cre^+^/Pten^flox/flox^/Klf5^flox/wt^*, and *Cre^+^/Pten^flox/flox^/Klf5^flox/flox^*.Figure 1Breeding strategy and deletion confirmation for prostatic knockout of *Klf5* and *Pten*. (A) Schematic of breeding design for the generation of mice with all six desired genotypes of *Klf5* and *Pten* using mouse strains of floxed *Klf5* (Klf5^F/F^), floxed *Pten* (Pten^F/F^) ,and PB-Cre4. F and W indicate floxed and wild-type alleles, respectively. (B and C) Detection of Klf5 protein expression by IHC staining in 6-month-old APs (B) and *Klf5* mRNA expression by real-time RT-PCR in the whole prostate of 6-month-old mice (C) with different *Klf5* deletion status and *Pten* homozygous deletion. (D and E) Detection of Pten protein expression by IHC staining in 6-month-old APs (D) and *Pten* mRNA expression by real-time RT-PCR in the whole prostate of 6-month-old mice (E) with different *Pten* deletion status. + and − indicate wild-type and deleted *Klf5* or *Pten* alleles, respectively; \* and \*\* indicate *P* \< .05 and *P* \< .01, respectively, based on Student\'s *t* test.

All mice were toe-clipped for identification and tail-clipped to collect tissues for genotyping at age 10 to 14 days. Freshly dissected tissues were washed in phosphate-buffered saline (PBS) to clean blood and incubated overnight at 56°C with tissue lysis buffer (100 mM Tris-HCl, 5 mM EDTA, 200 mM NaCl, 0.2% sodium dodecyl sulfate, 500 μg/ml proteinase K, pH 8.0) to release DNA. Diluted tissue lysates were used as templates for polymerase chain reaction (PCR)--based genotyping. PCR conditions were previously described [@bb0155]. Primer sequences and sizes of PCR products for genotyping the different genes are listed in [Table S1](#ec0005){ref-type="supplementary-material"}.

RNA Extraction and Real-Time PCR Assay {#s0035}
--------------------------------------

For mouse tissues, freshly dissected prostate tissues were immediately immersed into the RNAlater solution (Qiagen, Valencia, CA) for at least 16 hours at 4°C. Total RNA was then isolated using the RNeasy Mini Kit (Qiagen), following the manufacturer's instructions. For cultured cells, total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA) following the procedures established previously [@bb0160]. The first strand of cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).

Real-time reverse transcription (RT)--PCR was performed using the SYBR Premix Ex Taq reagent (Takara Otsu, Shiga, Japan) with the ABI Prism 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). The 2^(− ΔΔCt)^ method was used to calculate the relative fold change for a gene's expression, with the expression level of *GAPDH* as an internal control. Primers for real-time PCR assays are listed in [Table S1](#ec0005){ref-type="supplementary-material"}.

Microarray-Based Expression Profiling and Signaling Pathway Analysis {#s0040}
--------------------------------------------------------------------

The microarray experiment was performed at the Emory Integrated Genomics Core using standard procedures. Briefly, total RNA was extracted from dorsal prostates (DPs) of four pairs of 6-month-old mice with the genotype of *Pten*^−/−^;*Klf5*^+/+^ or *Pten*^−/−^;*Klf5*^−/−^. The quality of total RNA was confirmed using an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). After synthesis from the same amount of total RNA, the cDNA library for a tissue sample was hybridized to the Affymetrix Mouse Gene 1.0 ST Array, which covers 28,853 genes with approximately 27 probes per gene spread across the full length of each gene. Hybridization and washing and staining of probe arrays were performed according to Affymetrix's protocol. GeneChips were scanned using the Affymetrix 3000 scanner and images were converted to digital data, which were then analyzed by using the GeneSpring GX program (Agilent Technologies). The initial list of genes was generated with the preliminary data using mean polish and robust multi-array average (RMA) with GC content adjustment.

Genes were sorted by their *P* values between the wild-type *Klf5* and *Klf5*-null groups, and those with *P* \< .05 were considered differentially expressed. After ranking by the fold change of expression, differentially expressed genes were categorized into the following seven groups: 1.5 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 10, and \> 10 fold change of expression. For each group, four to seven genes were chosen and subjected to real-time RT-PCR to validate their differential expression with four to eight RNA samples, including the four used for microarray hybridization. On the basis of published studies using the same gene arrays [@bb0165], [@bb0170], [@bb0175] and the validation of 31 of 33 genes, we set the threshold of fold change to 1.5 to establish the list of differentially expressed genes for pathway and ontology analyses. The original microarray data have been deposited in National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus database and are accessible through Gene Expression Omnibus Series Accession No. GSE58719.

Differentially expressed genes and their expression levels were uploaded into the web-based MetaCore program (<http://thomsonreuters.com/metacore>), and different algorithms were run with MetaCore database to identify or build signaling pathways, gene ontology (GO)--based functional processes, and molecular networks that are modulated by *Klf5* deletion. For each of the 586 genes identified as prostate cancer--related genes by the Disease (by biomarkers) Ontology of MetaCore, a PubMed search with a gene's name and "prostate cancer" as search terms indicated that 203 of the genes had been studied in prostate cancer. The publications were evaluated to identify those genes that have been shown to functionally impact prostate cancer cell behavior \[proliferation, apoptosis, migration, epithelial-to-mesenchymal transition (EMT), metastasis, and so on\], undergo promoter methylation, or have expression abnormalities that are associated with clinical or pathologic characteristics of prostate cancer. The resultant 172 genes and their normalized log~2~ values of intensity differences between *Klf5* wild-type and *Klf5*-null groups were then subjected to the R software to generate a heat map.

Genes dysregulated by *Klf5* deletion in this study were also compared to those identified in previous studies [@bb0120], [@bb0165], [@bb0170], [@bb0175] to identify the genes that are regulated by Klf5 in different tissues or experimental systems.

Histopathologic Analysis {#s0045}
------------------------

Mice with different *Klf5* and *Pten* deletion status were sacrificed at various time points (4, 6, 9, 12, 15, and 18 months for the *Pten*^+/−^ group and 2, 4, and 6 months for the *Pten*^−/−^ group), and prostates were freshly collected and dissected in cold PBS. Tissues for histopathologic analysis were fixed in 3.7% neutral buffered formaldehyde overnight. Fixed tissues were then embedded in paraffin, sectioned at 5-μm thickness, and stained with hematoxylin and eosin (H&E) following standard protocols.

Pathologic diagnosis was performed by pathologists led by Dr Robert D. Cardiff through a paid service at the Center for Comparative Medicine, Department of Pathology, University of California at Davis. Published guidelines were followed [@bb0180], [@bb0185].

Immunohistochemical and Immunofluorescence Staining {#s0050}
---------------------------------------------------

For immunohistochemical (IHC) staining, tissue sections on glass slides were deparaffinized in xylene, rehydrated in graded ethanol solutions, and washed in tap water. Antigen retrieval was performed by boiling the slides in a pressure cooker for 3 minutes in a citrate buffer (10 mM trisodium citrate, pH 6.0). After 10-minute treatment with 3% H~2~O~2~, tissue sections were then blocked with 5% normal goat serum in Tris-buffered saline with 0.1% Tween-20 for 1 hour at room temperature, incubated with primary antibodies at 4°C overnight, and then incubated with EnVision Polymer-HRP secondary antibodies (Dako, Glostrup, Denmark) for 30 minutes at room temperature. After the application of DAB chromogen, tissue sections were stained with hematoxylin, dehydrated, and mounted. The slides were then scanned with a Hamamatsu NanoZoomer scanner (Hamamatsu Corporation, Bridgewater, NJ). For some proteins, cell numbers were counted to determine the positive rate.

For immunofluorescence (IF) staining, the same procedures of deparaffinization, rehydration, and antigen retrieval were followed. Tissue sections were then incubated with the blocking solution (10% normal goat serum and 1% BSA in PBS) for 1 hour at room temperature, with primary antibodies at 4°C overnight, and with secondary antibodies (Alexa Fluor dyes; Invitrogen) for 30 minutes at room temperature. After 4\',6-diamidino-2-phenylindole (DAPI) staining for nuclei, slides were mounted with anti-photobleaching mounting medium. Multichannel pictures were taken with a Zeiss Axioplan 2 Wide-Field Microscope (Carl Zeiss Microscopy, Thornwood, NY).

The primary antibodies used in this study (IHC or IF) and dilutions were given as follows: rabbit anti-KLF5 (IHC, 1:6000 dilution) [@bb0125], rabbit anti-PTEN (Cell Signaling Technology, Danvers, MA; IHC, 1:100), rabbit anti-Ki67 (Thermo Fisher Scientific, Waltham, MA; IHC, 1:200), rabbit anti--phospho-Akt (Cell Signaling Technology; IHC, 1:150), mouse anti--phospho-Erk1/2 (Cell Signaling Technology; IHC, 1:200), rabbit anti--phospho-mammalian target of rapamycin (mTOR) (Cell Signaling Technology; IHC, 1:100), rabbit anti--phospho-S6 (Cell Signaling Technology; IHC, 1:200), rabbit anti-p15/INK4B (Cell Signaling Technology; IHC, 1:1000), rabbit anti-CK5 (Covance, Princeton, NJ; IHC, 1:1000; IF, 1:200), mouse anti-Ck14 (Thermo Fisher Scientific; IF, 1:200), mouse anti-p63 (Santa Cruz Biotechnology, Santa Cruz, CA; IF, 1:100), rabbit anti-Ck18 (GeneTex, Irvine, CA; IHC, 1:1500; IF, 1:400), mouse anti--smooth muscle actin (Sma; Sigma-Aldrich, St Louis, MO; IHC, 1:5000), rabbit anti-EGF (Abcam, Cambridge, MA; IHC, 1:400), and rabbit anti--phospho--Egf receptor (Egfr) Y1068 (Cell Signaling Technology; IHC, 1:100).

Knockdown of *KLF5* and *PTEN* by RNA Interference {#s0055}
--------------------------------------------------

The PNT2 human prostate luminal cell line, originated from SV40-immortalized normal prostate epithelium, was purchased from Sigma and cultured in RPMI 1640 supplemented with 10% FBS. PNT2 cells were transfected with siRNAs against *KLF5*, *PTEN*, or the control with the X-tremeGENE HP transfection reagent (Roche, Nutley, NJ) to knock down the expression of *KLF5* or *PTEN*. Sequences of siRNAs were given as follows: siKLF5, AAGCUCACCUGAGGACUCATT [@bb0190]; siPTEN, AAGAUCUUGACCAAUGGCUAATT (Sigma); and siCtrl, AAUUCUCCGAACGUGUCACGUTT (Thermo Fisher Scientific).

Western Blot Analysis {#s0060}
---------------------

Western blot analysis was performed following previously established procedures [@bb0160]. The antibody against human KLF5 was prepared as previously described [@bb0070], and those against other proteins are given as follow: rabbit anti-PTEN, rabbit anti--phospho-AKT, rabbit anti--phospho-ERK, rabbit anti-AKT, rabbit anti-ERK, and rabbit anti--phospho-S6 were from Cell Signaling Technology; and rabbit anti--β-actin, rabbit anti-p15, and rabbit anti-mouse Klf5 were from Sigma, Santa Cruz Biotechnology, and Millipore (Temecula, CA), respectively.

Detection of Apoptosis by the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) Assay {#s0065}
--------------------------------------------------------------------------------------------------------

The TumorTACS *In Situ* Apoptosis Detection Kit (Trevigen, Gaithersburg, MD) was used for the TUNEL assay following manufacturer's instruction. Formalin-fixed prostate sections from 6-month-old mice were stained in triplicate for each genotype. Slides were then scanned, and the number of apoptotic cells and the number of total cells in the anterior and DPs were counted using ImageJ software to determine the percentage of apoptotic cells.

Statistical Analysis {#s0070}
--------------------

Statistical analyses were performed using the GraphPad Instat statistical computer program (GraphPad Software, Inc, La Jolla, CA). One-way analysis of variance was used to determine statistical differences among groups in the analysis of Ki67-positive rate, while the Chi-square analysis was used for differences in phenotype changes among the three Klf5 genotypes in [Table 1](#t0005){ref-type="table"}. *P* values less than .05 were considered statistically significant.Table 1Numbers of Mice with Hyperplasia (HP) and mPIN in the AP, DP, LP, and VP at Different Ages (Months) with Hemizygous Deletion of *Pten* and Different *Klf5* Deletion StatusKlf5 DeletionAPDPLPVPTotal MiceHPmPINHPmPINHPmPINHPmPIN4 to 6 months +/+213021303 +/−803517808 −/−5234347079 to 12 months +/+817152719 +/−48210\*\*210\*11112 −/−6309\*\*2772915 to 18 months +/+470114611011 +/−21301541113215 −/−3719188110All ages +/+149101211921123 +/−1421530\*728\*32335 −/−1412422\*61922326[^2]

Results {#s0015}
=======

Simultaneous Knockout of *Pten* and *Klf5* in Mouse Prostates {#s0075}
-------------------------------------------------------------

Three strains of mice, including floxed Klf5, floxed Pten, and PB-Cre4, were used to generate the following six desired genotypes: *Cre^+^/Pten^flox/wt^/Klf5^wt/wt^*, *Cre^+^/Pten^flox/wt^/Klf5^flox/wt^*, *Cre^+^/Pten^flox/wt^/Klf5^flox/flox^*, *Cre^+^/Pten^flox/flox^/Klf5^wt/wt^*, *Cre^+^/Pten^flox/flox^/Klf5^flox/wt^*, and *Cre^+^/Pten^flox/flox^/Klf5^flox/flox^* ([Figure 1](#f0005){ref-type="fig"}*A*). These mice were divided into two groups according to *Pten* deletion status, i.e., hemizygous deletion (Pten^+/−^) and homozygous deletion (Pten^−/−^; [Figure 1](#f0005){ref-type="fig"}*A*). All three strains of mice have been successfully used in previous studies [@bb0025], [@bb0125], and efficient gene knockout in the prostate was confirmed by examining the expression of *Pten* and *Klf5* at the mRNA and protein levels by real-time RT-PCR and IHC staining. The mRNA levels for both *Klf5* and *Pten* were reduced by about half in tissues with hemizygous deletion and the reduction was dramatic in tissues with homozygous deletion ([Figure 1](#f0005){ref-type="fig"}, *C* and *E*). The protein expression of Klf5 or Pten was also significantly decreased on genomic deletion of the respective gene ([Figures 1](#f0005){ref-type="fig"}, *B* and *D*, and W1, and data not shown). These results validated the knockout system for further analyses.

*Klf5* Deletion Accelerated the Development and Severity of mPIN Induced by *Pten* Hemizygous Deletion {#s0080}
------------------------------------------------------------------------------------------------------

Deletion of one *Pten* allele causes mPIN [@bb0025], so we first examined whether *Klf5* deletion affects mPIN development induced by hemizygous deletion of *Pten*. At 4 to 6 months of age, prostates with *Pten* hemizygous deletion alone (Pten^+/−^/Klf5^+/+^) began to show scattered hyperplasia, but no mPIN was noticeable. Simultaneous deletion of *Klf5*, either of one allele (Pten^+/−^/Klf5^+/−^) or both alleles (Pten^+/−^/Klf5^−/−^), caused the appearance of low-grade mPIN in both DP and lateral prostate (LP), which was characterized by multiple layers of larger cells with abundant pale cytoplasm ([Figure 2](#f0010){ref-type="fig"}, panels at the left). At 9 to 12 months of age, while single allele deletion of *Pten* (Pten^+/−^/Klf5^+/+^) caused low-grade mPIN (grades I and II), simultaneous deletion of *Klf5* (Pten^+/−^/Klf5^+/−^ and Pten^+/−^/Klf5^−/−^) caused high-grade (HG) mPIN (grades III and IV), as indicated by the filling of the lumen with excess cells that had an increased nucleus-to-cytoplasm ratio and small intraepithelial blood vessels ([Figure 2](#f0010){ref-type="fig"}, panels in the middle). At 15 to 18 months of age, while HG mPIN developed in some but not all prostates with *Pten* hemizygous deletion alone (Pten^+/−^/Klf5^+/+^), inactivation of one or both *Klf5* alleles (Pten^+/−^/Klf5^+/−^ and Pten^+/−^/Klf5^−/−^) caused more severe HG mPIN with higher nucleus-to-cytoplasm ratios. The large cell pattern seen with deletions of both *Pten* and *Klf5* was typical for AKT/PTEN-related tumors, further indicating a more severe cancer-related phenotype ([Figure 2](#f0010){ref-type="fig"}, panels at the right).Figure 2Deletion of *Klf5* accelerates the development and severity of mPIN induced by hemizygous deletion of *Pten*. H&E-stained tissue section images of DPs and LPs at 6, 12, and 18 months with *Klf5* and *Pten* deletions indicated. + and − indicate wild-type and deleted *Klf5* or *Pten* alleles, respectively.

We compared the incidence of mPIN between prostates with and without the deletion of *Klf5* and found that deletion of one or both *Klf5* alleles caused a statistically significant increase in the incidence of mPIN in mice 9 to 12 months old ([Table 1](#t0005){ref-type="table"}). When all age groups were combined, the difference was still statistically significant ([Table 1](#t0005){ref-type="table"}). We also noticed that *Klf5* deletion caused more severe abnormalities in the DP and LP ([Figure 2](#f0010){ref-type="fig"}) but less in the anterior prostate (AP) and ventral prostate (VP). In addition, few differences were noticeable between hemizygous and homozygous deletions of *Klf5* in the development and progression of mPIN ([Figure 2](#f0010){ref-type="fig"}), although hemizygous deletion of *Klf5* only decreased Klf5 expression in some cells ([Figure S1](#ec0045){ref-type="supplementary-material"}), indicating that *Klf5* is haploinsufficient and its haploinsufficiency is sufficient for the acceleration of *Pten* deletion--induced mPIN and related alterations.

*Klf5* Deletion Promoted *Pten* Deletion**--**Initiated Prostatic Tumorigenesis and Disrupted the Luminal Architecture of Tumors {#s0085}
--------------------------------------------------------------------------------------------------------------------------------

In the original study of *Pten* deletion in mouse prostates [@bb0025], *Pten* homozygous deletion caused invasive prostate cancer by the age of 9 weeks. In our study, prostate cancer was not detectable until the age of 16 weeks. We therefore focused on prostates at 6 months of age for analysis. Compared to prostates with *Pten* deletion alone at 6 months, those with both *Klf5* and *Pten* deletions showed an increase in the size of prostate glands, as visualized in H&E-stained whole gland tissue section, and *Klf5* homozygous deletion showed a more profound effect than *Klf5* hemizygous deletion ([Figure 3](#f0015){ref-type="fig"}, *upper row*).Figure 3Deletion of *Klf5* promotes the development and severity of prostate tumor induced by homozygous deletion of *Pten*. Upper row panels are images of H&E-stained tissue sections from the entire prostate gland at lower magnification, and lower row panels are magnified images of the boxed areas from the upper row panels. The prostates were from mice at 6 months of age. Note enlarged prostate glands and significant phenotypic alterations caused by *Klf5* deletion. Prostates from two mice are shown for each genotype. + and − indicate wild-type and deleted *Klf5* or *Pten* alleles, respectively.

Histologically, prostate tumors induced by *Pten* homozygous deletion alone maintained a luminal architecture ([Figure 3](#f0015){ref-type="fig"}), and necrosis was frequently observed in the center of the tumors, which is a common feature of HG mPIN and human prostate cancer due to insufficient nutrients. Interestingly, *Klf5* hemizygous deletion resulted in a decreased luminal space in the prostate gland, and *Klf5* homozygous deletion led to complete filling of the luminal space with tumor cells and thus the elimination of luminal architecture ([Figure 3](#f0015){ref-type="fig"}, lower panels of the Klf5^−/−^ group). In addition, necrotic areas in the tumors were decreased by deletion of one *Klf5* allele and abolished by deletion of both *Klf5* alleles. In prostates with hemizygous *Pten* deletion, *Klf5* deletion--enhanced mPIN mainly occurred in the DP and LP and the deletions of one or both *Klf5* alleles showed similar effects. In contrast, *Klf5* deletion caused morphologic abnormalities in *Pten*-null prostates in all four lobes, and deletion of both *Klf5* alleles clearly showed a more profound effect than the deletion of one *Klf5* allele ([Figure 3](#f0015){ref-type="fig"}).

Molecular Characterization of Architectural Abnormalities in Prostate Tumors with Deletions of *Klf5* and *Pten* {#s0090}
----------------------------------------------------------------------------------------------------------------

Since the luminal structure was almost eliminated in prostate tumors with *Klf5* and *Pten* deletions ([Figure 3](#f0015){ref-type="fig"}) and *Pten* deletion alone caused the expansion of the basal type of tumor cells, as indicated by positive staining for the Ck5 basal cell marker [@bb0195], we further evaluated whether *Klf5* deletion altered the luminal architecture of *Pten*-null tumors. We examined the expression of molecular markers for major components of prostatic architecture, including those for luminal cells (Ck18), basal cells (Ck5 and Ck14), and the fibromuscular stroma (Sma), in 6-month-old prostate tumors with both *Klf5* and *Pten* deletions. Without *Klf5* deletion, cells in *Pten*-null prostate tumors were mostly positive for either a luminal marker (Ck18) or a basal marker (Ck5 or Ck14), and few cells were positive for both markers ([Figure 4](#f0020){ref-type="fig"}, *A* and *B*), which is consistent with the findings in a previous study [@bb0195]. When *Klf5* was deleted, the number of basal cells decreased dramatically as indicated by the staining of Ck5 or Ck14 basal cell marker, while luminal cells, as indicated by positive staining for the Ck18 luminal cell marker, expanded and almost occupied the entire tumor ([Figure 4](#f0020){ref-type="fig"}, *A* and *B*). In *Pten* deletion--induced prostate tumors, expression of p63, a bona fide basal cell marker [@bb0200], was still restricted to basal layers, but Ck5 was expressed in both basal layers and cancerous acini [@bb0195], which was confirmed in our results ([Figure 4](#f0020){ref-type="fig"}*C*, *left row*). Interestingly, analysis of tumors with both *Klf5* and *Pten* deletions demonstrated that, while cells in basal layers still expressed both p63 and Ck5, almost no tumor cells in acini expressed Ck5 ([Figure 4](#f0020){ref-type="fig"}*C*), which is different from the effect of *Pten* deletion alone. These results indicate that *Klf5* deletion disrupts the ratio of Ck18-positive luminal cells to Ck5-positive basal cells in *Pten* deletion--induced prostate tumors.Figure 4Knockout of *Klf5* disrupts the architecture of prostate tumors induced by *Pten* deletion. Expression of basal cell markers Ck5, Ck14, and p63, luminal cell marker Ck18, and smooth muscle marker Sma was detected by IHC staining (A) or IF staining (B and C) in consecutive tissue sections (panel A only) of mouse prostates at 6 months of age. Pictures of basal and luminal markers were taken from the same area of tissue for better comparison (panel A only). DAPI staining was used to show nuclei (blue). Gene deletion status is indicated at the top and marker names at the left. The magnification for images of basal and luminal markers is × 200, and two magnifications are shown for Sma (× 10 in the upper and × 40 in the lower). + and − indicate the presence and absence of a *Klf5* or a *Pten* allele.

We also analyzed the expression of Sma, a marker for the layer of fibromuscular stroma often used to evaluate tumor invasion to the stroma [@bb0085]. Whereas loss of Sma expression with *Pten* deletion alone was reported in a previous study [@bb0025], our analysis demonstrated that in prostate tumors with *Pten* deletion alone, Sma was still expressed, and the layer of Sma-positive fibromuscular stroma was still intact for an acinus ([Figure 4](#f0020){ref-type="fig"}*A*, the lower panel in the left two rows). When one *Klf5* allele was deleted (Pten^−/−^/Klf5^+/−^), the surrounding smooth muscle layer became dramatically thinner, although it was still continuous. When both *Klf5* alleles were deleted (Pten^−/−^/Klf5^−/−^), the smooth muscle layer became discontinuous or totally absent for most acini in tumors ([Figure 4](#f0020){ref-type="fig"}*A*, the lower panel in the right two rows).

*Klf5* Deletion Dysregulates a Large Number of Genes {#s0095}
----------------------------------------------------

To understand how *Klf5* deletion promotes prostate tumorigenesis initiated by *Pten* deletion, we performed microarray analysis using DPs at 6 months with wild-type or homozygous deletion of *Klf5* in the *Pten*-null background. At 6 months, tumors were larger and had more severe phenotypic abnormalities ([Figure 3](#f0015){ref-type="fig"}). Using the Affymetrix mouse whole genome chips and associated computer programs, 7217 genes were identified on the basis of a significant (*P* \< .05) expression difference between *Klf5* wild-type and *Klf5*-null groups. In previous publications using the same expression chips, a \> 1.5-fold change combined with *P* \< .05 has been defined as the minimum meaningful fold change in the identification of differentially expressed genes [@bb0165], [@bb0170], [@bb0175]. Application of the same principle to our data resulted in a total of 1197 genes, 569 of which were upregulated and 628 were downregulated ([Table S2](#ec0010){ref-type="supplementary-material"}).

To evaluate the quality of the microarray data, we selected 33 genes with different degrees of differential expression in the microarray analysis and performed real-time RT-PCR in four to eight wild-type or *Klf5*-null DPs. Differential expression was validated between the two groups for 31 of the 33 (94%) genes ([Figure 5](#f0025){ref-type="fig"}, *A* and *B*). In addition, almost all of the 33 genes showed similar fold changes between microarray and real-time RT-PCR analyses except for *Klf5*, which showed a much more dramatic decrease in the real-time RT-PCR assay ([Figure 5](#f0025){ref-type="fig"}*B*). These results indicate a good quality of the microarray data.Figure 5Bioinformatic identification and analysis of *Klf5* deletion--dysregulated prostate cancer--related genes and molecular pathways in *Pten*-null mouse prostates. (A and B) Validation of differential expression for 13 upregulated (A) and 20 downregulated genes by real-time RT-PCR using the prostate samples including those used for microarray. White and black bars indicate microarray data and RT-PCR data, respectively. \**P* \< .05; \*\**P* \< .01. (C) Heat map of genes with \> 2.0-fold expression change between wild-type and *Klf5*-null mouse prostates and associated with prostate cancer based on PubMed publications. The four wild-type prostates and the four *Klf5*-null prostates were randomly paired for map drawing. Genes are clustered on the basis of their association with prostate cancer, with those positively affecting prostate cancer cell behavior or upregulated in prostate cancer marked as "positive", and those negatively affecting prostate cancer behavior or downregulated in prostate cancer marked as "negative". The number in the parentheses after each gene name indicates the number of PubMed publications available on that gene. The percentage of upregulated or downregulated genes is shown. (D) *Klf5* deletion activates canonical mitogenic signaling pathway involving AKT and ERK, as revealed by the analysis of *Klf5* deletion--dysregulated genes using the MetaCore program. Up-regulation of signal initiating growth factors, cytokines, chemokines, and receptors activates downstream effectors involved in different processes through multiple canonical signaling pathways. Different shapes of the nodes represent functional classifications of genes. Red and blue circles in the nodes indicate up-regulation and down-regulation, respectively, of genes. Lines between every two nodes indicate their interactions, with red for inhibition, green for activation, gray for unspecified interaction, and dashed for indirect interaction. Arrow indicates the direction of a regulation.

As a basic transcription factor, KLF5 could regulate a common set of genes among different types of tissues. Therefore, we compared our gene list with published data from other mouse tissues. Among the genes dysregulated by *Klf5* deletion during post-eyelid opening maturation of mouse corneas [@bb0205], 96 upregulated genes and 41 downregulated genes showed the same trends of changes, while 73 genes showed opposite changes compared to our data ([Table S3](#ec0015){ref-type="supplementary-material"}). Among the available partial list of genes dysregulated by *Klf5* deletion in intestine villus and bladder, a previous study identified 112 genes that are dysregulated (12 up and 100 down) by *Klf5* deletion in both tissues [@bb0175]. Twenty of the downregulated genes but none of the upregulated genes showed the same pattern of dysregulation in the prostate in our study ([Table S3](#ec0015){ref-type="supplementary-material"}). Two of the 20 genes, *Reep6* and *Dgat2*, were downregulated in all four mouse models.

In the DU 145 human prostate cancer cell line, in which one *PTEN* allele has been lost [@bb0210] and *KLF5* expression is rather low [@bb0050], RNA-Seq and data analysis showed that ectopic expression of *KLF5* or the acetylation-deficient K369R mutant of KLF5 changed the expression of many genes [@bb0120]. Seven of the 65 KLF5-regulated genes (39 up and 26 down) and 54 K369R-regulated genes were also dysregulated by *Klf5* deletion in mouse prostates ([Table S4](#ec0020){ref-type="supplementary-material"}). The *CHGA* gene, which encodes a neuroendocrine differentiation marker associated with higher Gleason score in human prostate cancer [@bb0215], was the only gene that was downregulated by *Klf5* deletion and K369R expression but upregulated by KLF5 expression, suggesting an up-regulation by acetylated KLF5.

Functional Processes and Molecular Pathways Modulated by *Klf5* Deletion in *Pten*-Null Mouse Prostates {#s0100}
-------------------------------------------------------------------------------------------------------

To explore the molecular mechanisms underlying *Klf5* deletion--promoted tumorigenesis in *Pten*-null mouse prostates, we uploaded the 1197 differentially expressed genes to the MetaCore platform to enrich genes by diseases and identify significant GO processes, signaling pathways, and molecular networks that are dysregulated by *Klf5* deletion.

Using the "Disease (by biomarker)" enrichment of the MetaCore program, we first collected all the genes that were associated with the disease of "prostate neoplasms", which included 586 genes. Searching the PubMed database with a gene name and "prostate cancer" as keywords for these 586 genes revealed that 203 of them had been reported in at least one publication on prostate cancer. On the basis of the publications, 104 of the 203 genes were positively associated with prostate cancer, as indicated by a promoting effect on various behaviors and up-regulation or DNA hypomethylation in prostate cancer cells; 68 of the 203 genes were negatively associated with prostate cancer, as indicated by an inhibitory effect on cancer cell behavior and down-regulation or DNA hypermethylation in cancer cells ([Table S5](#ec0025){ref-type="supplementary-material"}, [Figure S2](#ec0050){ref-type="supplementary-material"}), and the remaining 31 of the 203 genes had inconclusive information. Deletion of *Klf5* upregulated 70 of the 104 (67%) genes positively associated with prostate cancer and downregulated 37 of the 68 (54%) genes negatively associated with prostate cancer, which is consistent with the heat map generated by the R program using the 172 genes and their expression fold changes ([Figure S2](#ec0050){ref-type="supplementary-material"}). The expression fold change was greater than 2 for 58 of the 172 (34%) genes. For these 58 genes, 35 and 23 were positively and negatively, respectively, associated with prostate cancer. Twenty-six of the 35 (74%) positively associated genes were upregulated, while 17 of the 23 (74%) negatively associated genes were downregulated by *Klf5* deletion, which is obvious in the heat map for this group of genes ([Figure 5](#f0025){ref-type="fig"}*C*) and consistent with a tumor suppressor function of Klf5.

The GO analysis of the MetaCore program also identified a number of functional processes that were regulated by *Klf5* deletion, including some that are associated with tumorigenesis: blood vessel morphogenesis, cell adhesion, ECM remodeling, EMT, chemotaxis, and inflammation ([Table S6](#ec0030){ref-type="supplementary-material"}). *Klf5* deletion also altered a number of canonical signaling pathways, as revealed by the pathway analysis function of the MetaCore program based on functional processes ([Table S7](#ec0035){ref-type="supplementary-material"}). Consistent with a tumor suppressor function of Klf5, many of the pathways were activated by *Klf5* deletion and their activation was shown to enhance multiple tumorigenesis-related processes such as MAPK cascades, EMT, G-protein signaling, and chemotaxis, including extracellular growth factors such as EGF, PDGF-B, and PDGF-D; cell membrane tyrosine kinase receptors such as ERBB4 and PDGFRβ; cytokine IL-1; and chemokines and chemokine receptor such as CXCL1, CXCL2, CXCR2, and so on ([Table S7](#ec0035){ref-type="supplementary-material"}). These nine molecules are all located at the originating point of specific signaling pathways, and their expression changes could thus drive cascades of signaling changes. We applied the "batch search" program of MetaCore to these nine genes and used MetaCore's "expand by one interaction" algorithm with all 1197 *Klf5* deletion--dysregulated genes as "activated experiment" data to build networks and identify overconnected pathways that are most relevant to *Klf5* deletion. Among the overconnected pathways identified, six were most overconnected, including AKT, ERK, NF-κB, protein kinase Cβ, p38, and PPARγ. Of all the pathways identified in [Table S7](#ec0035){ref-type="supplementary-material"}, AKT and ERK appeared in 12 and 11 of them, respectively, whereas NF-κB, protein kinase Cβ, p38, and PPARγ appeared in 5, 4, 3, and 1 of them, respectively. We therefore focused on AKT and ERK to draw the pathway map of molecules that were dysregulated by *Klf5* deletion, including the nine signal initiation molecules and some of their downstream effectors (p18, cyclin D2, Spp1, S6, and 4E-BP1). Molecules that were between an initiating molecule and an effector and not affected by *Klf5* deletion were eliminated from the map, resulting a schematic pathway map that suggests that *Klf5* deletion activates AKT and ERK signaling in the regulation of cell cycle, invasion, and protein synthesis ([Figure 5](#f0025){ref-type="fig"}*D*).

In addition to the canonical pathways affected by *Klf5* deletion ([Table S7](#ec0035){ref-type="supplementary-material"} and [Figure 5](#f0025){ref-type="fig"}*D*), there could be novel networks affected by *Klf5* deletion. We therefore built molecular networks involving *Klf5* deletion--dysregulated genes with the network analysis algorithm of MetaCore. Networks with 50 total nodes and \> 4 seed nodes (differentially expressed genes) were considered instructive and meaningful. Among the 25 networks built, 20 centered around CREB1, 2 centered around SP1 (ranked the first and third based on *P* values), and one each centered on Myc and RhoA ([Figure S3](#ec0055){ref-type="supplementary-material"}). Similarly, 21 transcription factor--centered networks were also identified, of which CREB1 and SP1 were the first and second most significantly involved, while ER, Myc, and AR ranked third, fourth, and fifth, respectively ([Table S8](#ec0040){ref-type="supplementary-material"}). These five molecules (CREB1, SP1, Myc, ER, and AR) and the *Klf5* deletion--dysregulated genes that are directly regulated by these molecules are listed in [Table 2](#t0010){ref-type="table"}.Table 2Key Molecules Potentially Cooperating with Klf5 to Mediate *Klf5* Deletion--Promoted Tumorigenesis, as Identified by the Network Analysis of MetaCore with *Klf5* Deletion--Dysregulated Genes, and Those Differentially Expressed Genes that Are Also Direct Transcriptional Targets of These Key MoleculesKey MoleculesGenes Regulated by *Klf5* DeletionCREB1*Upregulated*: Spp1, Tac1, Slc1a2, Egf, Ccnd2, Arg2, Msr1, Sstr2, Rgs2, Il1a, Gja1, Gzmb, Sfrp1, Selp, Vcam1, Cck, Tgm1, Il1b, Pfkfb3, Rgs1, Spry2, Mat2a, Pgf, and Map2. *Downregulated*: Ldlr, Bhlhe40, Zfp667, Avpi1, Pmaip1, Bcl2, Ndn, Cdo1, Ppp2r2b, Kcnh2, Kcne4, Cd14, Ppargc1b, Pparg, Agt, Chga, Muc4, Fam3b, Muc5b, and Ptges.SP1*Upregulated*: Crabp1, Abo, Cbs, Spp1, Slc9a2, Bhlha15, Chil1, Ccl20, Ccnd2, Padi2, Nkx3-1, Cyp7b1, Klf8, Prlr, Trf, Ednrb, Raver2, Sstr2, Slc6a2, Ggt1, Tnc, Fbn1, Rgs2, Anxa6, Il1a, Serpina1a, Gja1, Bmp7, Serpina3n, Cd7, Pla2g7, Trem1, Crabp2, Selp, Vcam1, Cad, Pdgfd, Cck, Pdgfrb, Mgst1, Soat1, Tnnt2, Tgm1, Col1a1, Col1a1, Timp1, Kcnj2, Flt1, Col1a2, Col1a2, Aqp1, Slc5a8, Gstm7, Adm, Slc19a2, Apln, Col4a2, Angpt2, Spry2, Itgax, Mat2a, Ctns, Hdc, Padi3, Pdgfb, Fcgr4, Slc11a1, Aox1, Col4a1, Hhex, Nrp1, Cited2, Mgarp, Tfpi2, Phgdh, Mir365-1, Tlr13, and Eng. *Downregulated*: Stard3, Hcn2, Atp6ap2, Ldlr, Idh2, Mbp, Adam23, Cdkn2c, Bhlhe40, Cyp21a1, Zfp667, Ggh, Akap12, Cdk6, Noxo1, Cdh2, Atp4a, Efnb2, Bcl2, Ppl, Tnxb, Ppp2r2b, Ascl1, Kcnh2, S100a6, Smpd3, F3, Acacb, Mst1r, Cd14, Tmprss2, Klf5, Tnfsf10, Napepld, Upk1b, Chga, Cyp2f2, Ces1d, Clcn2, Hpse, Muc4, Kcnq1, Gpc3, Muc5b, Scnn1a, Krt7, Atp2a3, Ctse, Muc1, Ptges, Ltf, Hsd11b2, and Tff3.MYC*Upregulated*: Cbs, Spp1, Ccnd2, Fah, Ak4, Eif4ebp1, Bmp7, Sfrp1, Lox, Vcam1, Cad, Cck, Pdgfrb, Mgst1, Jag2, Adm, Rgs1, Itgax, Mt1, Cdh3, Sema6a, Angptl4, Slc11a1, Ndrg1, Cited2, Slc16a1, Bnip3, Spred2, and Alb. *Downregulated*: Mcm6, Abcd3, Vav2, Wnt5a, Ggh, Pmaip1, Rad51b, Cdk6, Nans, Bcl2, Mir200a, Peg10, Apol7a, Itpr2, Hmgcs2, Camk1d, Golm1, Rasgef1a, Gldc, Mir429, Casp1, Wnt4, Ppargc1b, Sestd1, Sox2, Pparg, Fa2h, Gpc3, and Hsd11b2.ER*Upregulated*: Ttr, Spp1, Ugt2b35, Erbb4, Slc1a2, Plod2, Cyp7b1, Prlr, Trf, Ccl28, Stc2, Sstr2, Mme, Mir181b-1, St3gal4, Gja1, Fam132a, Bmp7, Serpina3n, Thbs2, Cad, Rab31, Flt1, Aqp1, Adm, Pfkfb3, Mir181b-2, Cdh3, Adamts9, Padi3, Abtb2, Fcgr4, Mgarp, and Lamb1. *Downregulated*: Fabp6, Abcd3, Bcas1, Anxa3, Rap1gap, Cobl, Foxc1, Pmaip1, Mcf2l, Sytl2, Rad51b, Cdk6, Klf10, S100a6, Agr2, Mall, F3, Wnt4, Spire2, Por, Rapgefl1, Galnt4, Hsh2d, Agt, Ret, Sult1e1, Elf3, Gsta4, Krt7, Atp2a3, Muc1, Ptges, Ltf, Cyp2b10, Krt4, Tff3, and Psca.AR*Upregulated*: Spp1, Slc9a2, Ugt2b35, Azgp1, Ank, Nrn1, Nkx3-1, Pycr1, Mme, Eppin, Steap4, Cxcl2, Efna3, Pdgfrl, Slc19a2, Osbpl1a, Cxcl1, Gpr153, Cdh3, Angptl4, Ndrg1, Nrp1, and Cited2. *Downregulated*: AA986860, Pmaip1, Cdh2, Rab3b, Ppfibp2, Peg10, Agr2, F3, Mir31, Tmprss2, Klf5, Sox2, Pparg, Sult1e1, Scnn1a, Krt7, Muc1, and Psca.

EGF Was Dramatically Upregulated by *Klf5* Deletion in the *Pten*-Null Background {#s0105}
---------------------------------------------------------------------------------

Whereas multiple growth factors and cytokines were significantly upregulated by *Klf5* deletion in the microarray experiment, the *Egf* showed the highest fold change (2.97-fold). Considering the well-established role of EGF and its downstream signaling in cell proliferation and tumorigenesis, we performed additional experiments to test whether KLF5 regulates EGF transcription. Real-time RT-PCR was performed with DP samples (6 months old, eight samples for each of the three *Klf5* genotypes, including the four with wild-type or *Klf5*-null genotype used in microarray hybridization), and up-regulation of *Egf* by homozygous deletion of *Klf5* was confirmed in the *Pten*-null background ([Figure 6](#f0030){ref-type="fig"}*A*). Hemizygous deletion of *Klf5* did not show an effect though ([Figure 6](#f0030){ref-type="fig"}*A*). We also detected Egf protein by IHC staining in the same samples used for RNA detection and obtained consistent results: Egf protein showed an evident increase in *Klf5*-null prostates but no change in prostates with hemizygous deletion of *Klf5* ([Figure 6](#f0030){ref-type="fig"}*B*). We further tested the effect of *KLF5* on *EGF* expression in the context of PTEN using the PNT2 human prostate luminal cell line, in which proliferation signaling is activated by SV40 [@bb0220]. RNA interference was applied to knock down *KLF5* and/or *PTEN*, and the knockdown effect was confirmed by Western blot analysis ([Figure 6](#f0030){ref-type="fig"}*C*). Real-time RT-PCR demonstrated that, while knockdown of *PTEN* alone did not cause an apparent change in *EGF* expression, knockdown of *KLF5* significantly increased *EGF* mRNA level (*P* \< .01), and the increase was further enhanced by the knockdown of *PTEN* (*P* \< .02) ([Figure 6](#f0030){ref-type="fig"}*D*). We then examined whether Egf up-regulation by *Klf5* deletion in *Pten*-null mouse tumors has a functional effect by measuring the activity of Egfr. IHC staining demonstrated that the Y1068 phosphorylation of Egfr, an indication of Egfr activity [@bb0225], was clearly increased in *Klf5*-null prostates ([Figure 6](#f0030){ref-type="fig"}*E*), indicating that *Klf5* deletion further enhances the EGF/EGFR/MAPK signaling activity.Figure 6*Klf5* deletion upregulates EGF in *Pten*-null mouse prostate tumors and human prostate epithelial cell line. (A, B, and E) Detection of *EGF* mRNA expression by real-time RT-PCR (A) and Egf and p-Egfr proteins by IHC staining (B and E) in 6-month-old *Pten*-null mouse DPs with indicated *Klf5* deletion status. Data for each genotype in A was from eight mice. (C and D) Detection of protein expression of KLF5 and PTEN by Western blot analysis (C) and mRNA expression of *KLF5*, *PTEN*, and *EGF* by real-time RT-PCR (D) in the PNT2 immortalized human prostate luminal epithelial cell line with the knockdown of *KLF5*, *PTEN*, or both by RNA interference.

Deletion of *Klf5* Increased Cell Proliferation with Consistent Changes in the Expression of Proliferation-Related Molecules {#s0110}
----------------------------------------------------------------------------------------------------------------------------

On the basis of the findings that *Klf5* deletion significantly increased the size of *Pten* deletion--induced tumors ([Figure 3](#f0015){ref-type="fig"}), cell proliferation is increased by *Pten* deletion alone [@bb0025]. We determined whether *Klf5* deletion causes more cells to proliferate. Expression of the Ki67 proliferation marker was determined by IHC staining in each of the prostate lobes, and the rate of Ki67 positivity in tumor cells was calculated. While *Klf5* hemizygous deletion did not cause an obvious change in the rate of Ki67-positive cells, *Klf5* homozygous deletion significantly increased the rate ([Figure 7](#f0035){ref-type="fig"}*A*), indicating that homozygous deletion of *Klf5* increases cell proliferation in *Pten* deletion--induced prostate tumors.Figure 7Molecular characterization of prostate tumors induced by *Klf5* and *Pten* deletion. (A) IHC staining of the Ki67 proliferation marker, oncogenic kinases p-Akt, p-Erk1/2, and p-S6, and the p15 cell cycle inhibitor in tissue sections of APs at 6 months of age with different deletion status of *Klf5* and *Pten*. Marker names are indicated at the left, and the deletion status of genes is indicated at the top. The ratio (%) of Ki67-positive cells, as determined by cell counting, is shown at the lower right corner of each image of the Ki67 panels. (B) Detection of protein expression for Klf5, p-Akt, Akt, p-Erk1/2, Erk1/2, p-S6, p15, and β-actin by Western blot analysis in tissue lysates from anterior mouse prostates with the same genotype and age used in A. Relative protein level was determined by using the ImageJ software, and statistical significance was evaluated by using Student's *t* test. Marker names are indicated at the left, and the deletion status of genes is indicated at the top. + and − indicate the presence and absence of an allele for *Klf5* and *Pten*. \**P* \< .05; \*\**P* \< .01.

Our microarray analyses indicated that *Klf5* deletion increased the expression of genes positively associated with prostate cancer behaviors, activated mitogenic signaling pathways including AKT and ERK signaling pathways, and enhanced the EGF/EGFR signaling ([Figures 5](#f0025){ref-type="fig"}, *C* and *D*, and [6](#f0030){ref-type="fig"}, *A*, *B*, and *E*). Loss of PTEN enhances PI3K/AKT signaling [@bb0230] to increase cell proliferation, KLF5 has been linked to Ras/MAPK proliferation signaling [@bb0100], [@bb0110], and loss of KLF5 downregulates the p15 cell cycle inhibitor in the context of transforming growth factor--β (TGF-β) [@bb0190], [@bb0235]. We therefore evaluated the expression of key players in the PI3K/AKT signaling pathway including phosphorylated Akt (p-Akt), phosphorylated Erk1/2 (p-Erk1/2), phosphorylated mTor (p-mTor), phosphorylated S6 (p-S6), and p15 cell cycle inhibitor by IHC staining and Western blot analysis in *Pten*-null prostate tumors at 6 months of age. While hemizygous deletion of *Klf5* mildly increased the expression of p-Akt and p-S6, homozygous deletion of *Klf5* led to much more dramatic increases in their expression ([Figure 7](#f0035){ref-type="fig"}, *A* and *B*), indicating that *Klf5* deletion significantly enhances the effect of *Pten* deletion on PI3K/Akt signaling. Expression of p-Erk1/2 showed a similar pattern, with a much greater increase by *Klf5* homozygous deletion than that by *Klf5* hemizygous deletion ([Figure 7](#f0035){ref-type="fig"}, *A* and *B*). These results support the findings from MetaCore's pathway analysis. For p15, hemizygous deletion of *Klf5* decreased nuclear staining, and homozygous deletion of *Klf5* led to a more significant decrease in p15 expression ([Figure 7](#f0035){ref-type="fig"}, *A* and *B*). Although mTor is one of the crucial players in PI3K/Akt signaling, we were unable to detect p-mTor by Western blot analysis and detected few cells that were positive in IHC staining for p-mTor in *Klf5*-null tumors ([Figure S4](#ec0060){ref-type="supplementary-material"}), suggesting that p-mTor is less relevant in *Klf5*-null tumors.

Discussion {#s0020}
==========

*Klf5* Deletion Promotes *Pten* Deletion--Induced Prostatic Tumorigenesis {#s0115}
-------------------------------------------------------------------------

The current literature is somewhat inconsistent about the function of KLF5 in tumor development. On the one hand, KLF5 promotes tumor growth in xenograft models [@bb0095], [@bb0240], is necessary for intestinal tumorigenesis in genetically modified mice [@bb0245], and mediates Ras activation--induced intestinal tumorigenesis [@bb0110], [@bb0115]. On the other hand, KLF5 can also suppress tumorigenesis in xenograft models [@bb0090], [@bb0250]. Using a tissue-specific knockout mouse model, which provides more definitive evidence for the function of a given tumor suppressor gene, we were able to prove the tumor suppressor activity of KLF5. For example, in mouse prostates with hemizygous deletion of *Pten*, which develop mPIN [@bb0025], simultaneous deletion of *Klf5* shortened the latency of mPIN development and caused more severe phenotypic alterations in the mPIN ([Figure 2](#f0010){ref-type="fig"}). When both *Pten* alleles were deleted, which alone causes prostate cancer [@bb0025], *Klf5* deletion caused more rapid tumor growth and more severe phenotypic and molecular alterations in cancer ([Figure 3](#f0015){ref-type="fig"}, [Figure 4](#f0020){ref-type="fig"}, [Figure 5](#f0025){ref-type="fig"}, [Figure 6](#f0030){ref-type="fig"}, [Figure 7](#f0035){ref-type="fig"}).

In various human cancers including prostate cancer, deletion of the *KLF5* locus is the second most frequent chromosomal deletion, occurring in about 42% of tumors [@bb0045], [@bb0255]. KLF5 is also inactivated in more than 20% of human cancers through excess protein degradation mediated by the amplification and overexpression of the WWP1 oncogenic ubiquitin E3 ligase [@bb0075], [@bb0260], [@bb0265], [@bb0270]. The establishment of a tumor-promoting effect of *Klf5* deletion in this study suggests that *KLF5* inactivation could impact more than half of human cancers.

While *Klf5* deletion clearly promoted the development of prostate cancer initiated by *Pten* deletion ([Figure 2](#f0010){ref-type="fig"}, [Figure 3](#f0015){ref-type="fig"}), our previous study indicated that deletion of *Klf5* alone in prostatic epithelial cells does not have a pro-tumorigenic effect [@bb0125], as hemizygous deletion of *Klf5* caused hyperplasia with increased cell proliferation but did not cause neoplasms, and homozygous deletion of *Klf5* induced apoptosis without causing detectable cell proliferation [@bb0125]. Multiple genetic events are usually necessary for a tumor to form and progress, and it appears that at least another oncogenic event, such as *Pten* deletion, is necessary to release the pro-tumorigenic effect of *Klf5* deletion.

In human prostate cancer, a number of chromosomal regions are deleted or amplified, and deletions of *NKX3-1* at 8p21, *KLF5* at 13q21, and *PTEN* at 10q23 are among the most common deletions [@bb0005], and at least some prostate cancers possess the deletions of both *KLF5* and *PTEN* loci. For example, the LNCaP prostate cancer cell line has a 2-bp homozygous deletion of *PTEN* [@bb0145] and a hemizygous deletion of *KLF5* [@bb0050], and prostate cancer xenografts PC82 and LuCaP 58 have loss of both *PTEN* and *KLF5* loci [@bb0050], [@bb0275], [@bb0280], [@bb0285]. Our findings in this study thus establish a positive interaction between *KLF5* and *PTEN* deletions in prostatic carcinogenesis. They also provide a mouse model of prostate cancer involving two common genetic alterations in human prostate cancer.

In addition to the additive effect between *Pten* and *Klf5* deletions described above, *Pten* deletion also interacts with *Nkx3-1* deletion in prostatic carcinogenesis [@bb0290], [@bb0295]. Deletions of *Klf5* and *Nkx3-1*, however, do not appear to have an additive effect [@bb0300]. PTEN is an inhibitor of the PI3K/AKT signaling pathway, and PTEN loss leads to increased PI3K/AKT signaling activities that enhance both cell proliferation and survival [@bb0135], [@bb0305].

While homozygous deletion of *Klf5* alone increases cell death at least at age 18 months, as demonstrated in our previous study [@bb0125], it did not show a similar effect in *Pten*-null prostate tumors at 6 months of age ([Figure S5](#ec0065){ref-type="supplementary-material"}); it rather enhanced cell proliferation significantly in these tumors ([Figure 7](#f0035){ref-type="fig"}*A*). It is well established that *Pten* loss leads to the activation of the PI3K/AKT signaling, which is pro-survival [@bb0310], [@bb0315]. It is thus possible that enhanced survival by PI3K/AKT activation overcomes cell death induced by *Klf5* homozygous deletion, thus unmasking the tumor-promoting effect of *Klf5* homozygous deletion by activating multiple oncogenic signaling pathways including those described in our recent study [@bb0120]. The same mechanism could apply to other tumor suppressors that are part of the TGF-β signaling pathway and whose deletions have a positive interaction with *Pten* deletion in tumor development, including Smad4 and p27 [@bb0040], [@bb0320]. Furthermore, it is possible that other signaling pathways that prevent cell death could also unmask pro-tumorigenic functions of *Klf5* deletion, which remains unexplored.

*Klf5* Deletion Promotes the Luminal but Attenuates the Basal Type of *Pten* Deletion--Induced Prostate Tumor Cells {#s0120}
-------------------------------------------------------------------------------------------------------------------

Most human prostate cancers have a luminal phenotype, and very few (\< 1%) human prostate cancer cells express basal cell markers [@bb0325]. In addition, it appears that cells in both the basal and luminal layers can be transformed to give rise to prostate cancer [@bb0330]. In *Pten* deletion--induced mouse prostate tumors, the basal cell population is expanded to the acinus with an increased expression of the PSCA transient amplifying cell marker [@bb0025], [@bb0195], [@bb0335], indicating a more profound promoting effect of *Pten* deletion on basal cells during tumorigenesis. Unexpectedly, *Klf5* deletion reversed the effect of *Pten* deletion on the ratio of basal to luminal cells in prostate tumors. While *Klf5* deletion significantly increased the number of luminal tumor cells, which could be due to increased proliferation of this type of cells as indicated by the percentage of Ki67-expressing cells ([Figure 7](#f0035){ref-type="fig"}*A*), it actually diminished the number of basal tumor cells, as indicated by Ck5 expression (p63 −), in the cancerous acini ([Figure 4](#f0020){ref-type="fig"}*B*). Basal cells in the basal layers, as identified by p63 expression, were not affected ([Figure 4](#f0020){ref-type="fig"}*C*). Therefore, the tumor-promoting effect of *Klf5* deletion appears to be restricted to luminal tumor cells. Whereas the increase in the luminal to basal ratio by *Klf5* deletion could result from the differentiation of *Pten* deletion--induced Ck5^+^/p63^−^ TA cells, it is more likely that *Klf5* deletion causes the death or prevents the proliferation of Ck5^+^/p63^−^ TA cells, because these cells were almost absent in cancerous acini ([Figure 4](#f0020){ref-type="fig"}*C*) and the expression of the PSCA marker for such cells was dramatically reduced (more than 80-fold) on *Klf5* deletion ([Figure 5](#f0025){ref-type="fig"}, *B* and *C*, and [Table S2](#ec0010){ref-type="supplementary-material"}). Another possibility is that *Klf5* deletion prevented the differentiation of p63^+^/Ck5^+^ cells in the basal layer into Ck5^+^/p63^−^ TA cells. To fully address whether *Klf5* deletion has different effects on basal and luminal cells, it is necessary to perform additional studies using approaches such as lineage tracing and luminal or basal cell--specific Cre mice.

In normal prostates, our previous study suggests that Klf5 could also have different or even opposing functions in basal and luminal cells [@bb0125]. For example, whereas Klf5 is expressed in both luminal and basal cells, the protein is typically acetylated in luminal cells (AcKlf5) while unacetylated in basal cells (unAcKlf5) [@bb0125], and AcKLF5 and unAcKLF5 suppress and promotes, respectively, cell proliferation and tumor growth [@bb0120], [@bb0190]. Taken together with the different effects of *Klf5* deletion on luminal and basal tumor cells, we propose that unAcKLF5 is necessary for basal cell proliferation and AcKLF5 is necessary for luminal differentiation. We further propose that *Klf5* deletion compromises the pro-differentiation function of AcKLF5, leading to partial dedifferentiation and subsequent proliferation of luminal cells while attenuating the proliferation or survival of basal cells in *Pten*-null prostates. We are currently testing these predictions by developing a mouse model in which acetylation-deficient *Klf5* replaces wild-type *Klf5* in the prostate.

*Klf5* Deletion Promotes Cancer Cell Proliferation by Multiple Mechanisms {#s0125}
-------------------------------------------------------------------------

In understanding how *Klf5* deletion promotes *Pten* deletion--initiated prostatic tumorigenesis, microarray-based expression profiling and molecular pathway/network analysis indicated that a large number of genes involved in a number of molecular signaling pathways are dysregulated by *Klf5* deletion. One significant group of upregulated molecules included extracellular growth factors EGF and PDGFs, cytokine IL-1, chemokines CXCL and CCL, and tyrosine kinase and chemokine receptors ERBB4, PDGFR, and CXCR2 ([Table S2](#ec0010){ref-type="supplementary-material"}, [Table S7](#ec0035){ref-type="supplementary-material"} and [Figure 5](#f0025){ref-type="fig"}). *Egf*, in particular, is downregulated by *Pten* deletion alone [@bb0025] but was upregulated by *Klf5* deletion in the *Pten*-null background ([Figures 5](#f0025){ref-type="fig"}, *A* and *C*, and [6](#f0030){ref-type="fig"}*A*). Up-regulation of Egf protein and activation of Egfr by *Klf5* deletion were also detected by IHC staining in mouse prostates ([Figure 6](#f0030){ref-type="fig"}, *B* and *E*). Consistently, in the PNT2 human prostate epithelial cell line, knockdown of *PTEN* alone slightly downregulated but knockdown of *KLF5* alone or in combination with *PTEN* knockdown significantly regulated *EGF* mRNA expression ([Figure 6](#f0030){ref-type="fig"}*D*). EGF is a potent growth factor that activates AKT and ERK signaling [@bb0340], [@bb0345], further implicating AKT and ERK in *Klf5* deletion--promoted tumorigenesis. Up-regulation of Egf by *Klf5* deletion could therefore be one of the driving factors underlying *Klf5* deletion--promoted cell proliferation and tumorigenesis. This possibility remains to be tested.

Taken together with previous observations that *Pten* deletion--initiated mouse prostate tumors have an increased rate of cell proliferation due to the activation of PI3K/AKT and MAPK signaling [@bb0025], [@bb0135], [@bb0305], [@bb0350], [@bb0355], we determined the effects of *Klf5* deletion on cell proliferation and AKT and ERK activities in *Pten*-null prostate tumors. When *Klf5* was homozygously deleted, the cell proliferation rate more than doubled ([Figure 7](#f0035){ref-type="fig"}*A*, Ki67 panel), the expression of p-Akt and Erk were obviously increased ([Figure 7](#f0035){ref-type="fig"}*A*), and the rate of cell death was unaffected ([Figure S5](#ec0065){ref-type="supplementary-material"}). Expression of activated Akt and Erk and their downstream molecule p-S6 [@bb0135], [@bb0360] was significantly increased, while p-mTor was slightly upregulated. These results indicate that *Klf5* deletion further promotes the proliferation of tumor cells, and an enhanced PI3K/AKT mitogenic signaling pathway is involved. KLF5 itself directly regulates the p15 cell cycle inhibitor in cell proliferation [@bb0190], [@bb0235], and this mechanism also appeared to function in *Pten* and *Klf5*-null prostate tumors, where *Klf5* deletion led to decreased p15 expression in a dose-dependent manner ([Figure 7](#f0035){ref-type="fig"}, *A* and *B*). Therefore, *Klf5* deletion likely mediates more rapid tumor growth by multiple pro-proliferative molecular pathways.

In a previous study, homozygous deletion of *Pten* in mouse prostates induced invasive adenocarcinoma and subsequent metastasis to the lymph node and lung at 4 months of age [@bb0025]. In our study, however, no tumor invasion, based on Sma staining, or metastasis, based on the dissection of lungs and livers, was evident in mice carrying *Pten*- and *Klf5*-null tumors even at 6 months of age. However, *Klf5* deletion could still promote tumor invasion and metastasis. For example, *Klf5* deletion led to a thinner or discontinuous smooth muscle layer ([Figure 4](#f0020){ref-type="fig"}) and the up-regulation of multiple matrix metalloproteinases, including MMP-12, MMP-13, and MMP-8 ([Figure 5](#f0025){ref-type="fig"}*A* and [Table S2](#ec0010){ref-type="supplementary-material"}). In addition, *Klf5* deletion also upregulated *Spp1*, one of four signature molecules predictive of prostate cancer metastasis [@bb0040], and KLF5 inactivation promoted EMT, a strong indicator of tumor invasion and metastasis, by downregulating miR-200 micro-RNAs [@bb0365]. *Klf5* deletion also downregulated miR-200 genes in mouse prostates ([Table S2](#ec0010){ref-type="supplementary-material"}, [Table S6](#ec0030){ref-type="supplementary-material"}, [Table S7](#ec0035){ref-type="supplementary-material"}). Therefore *Klf5* deletion could still promote tumor invasion and metastasis, and the lack of metastasis in this study could be caused by multiple reasons, including insufficient time for tumor progression and variation in genetic background among different mouse strains.

Multiple Molecules Could Cooperate with Klf5 in Gene Regulation {#s0130}
---------------------------------------------------------------

Despite the fact that KLF5 functions in a variety of pathophysiological processes in a context-dependent manner in various tissues [@bb0120], [@bb0190], [@bb0255], a large number of the same genes dysregulated by *Klf5* deletion in mouse prostate tumors were also regulated by KLF5 or its acetylation-deficient mutant K369R in xenograft tumors of the DU 145 human prostate cancer cell line ([Table S4](#ec0020){ref-type="supplementary-material"}). A large number of the same genes were also dysregulated by *Klf5* deletion across multiple types of tissues including cornea, villus, and bladder ([Table S3](#ec0015){ref-type="supplementary-material"}), suggesting that there is a common set of genes that is regulated by Klf5 in different tissues or under different contexts.

In identifying novel pathways and networks affected by *Klf5* deletion using the *Klf5* deletion--dysregulated genes, we found that CREB1, SP1, and Myc were the most significantly affected ([Figure S3](#ec0055){ref-type="supplementary-material"} and [Table 2](#t0010){ref-type="table"}), all of which are transcription factors. Network analysis for transcription factors identified five transcription factors that most significantly related to *Klf5* deletion--dysregulated genes, and CREB1, SP1, and Myc were again among the five. The other two transcription factors among the top 5 were ER and AR ([Tables 2](#t0010){ref-type="table"} and S8). Interestingly, the same five transcription factors were also identified as the most relevant molecules to the function of KLF5 and K369R in the DU 145 human prostate cancer cell [@bb0120]. It is thus possible that, as a transcription factor, KLF5 cooperates with CREB1, SP1, Myc, ER, and AR, e.g., in a transcription complex, to maintain the normal homeostasis of prostate epithelium, and disruption of this complex could promote tumorigenesis.

Some published studies support this possibility. For example, in human prostate cancer cells, KLF5 has been demonstrated to suppress tumor growth by forming a transcriptional complex with CREB1 and ERβ to upregulate the *FOXO1* tumor suppressor gene [@bb0090]. Phosphorylation of CREB1 is a classic mechanism of CREB1 activation [@bb0370], so it is worth testing whether CREB1 phosphorylation affects KLF5 function. ERα has also been shown to physically interact with KLF5 in gene regulation and cell proliferation in ERα-positive breast cancer cells [@bb0375]. Sp1 and KLF5 belong to the same family of Krüppel-like factors that bind to GC-rich promoter elements [@bb0380], so they may both bind to promoters of the same genes to cooperate, although this idea has not been tested. For Myc, not only is its gene transcription directly regulated by KLF5 [@bb0385], it also directly interacts with KLF5 in a TGF-β--dependent manner to regulate cell proliferation [@bb0235]. AR is essential for both the normal development and function of the prostate gland and the growth of prostate cancer [@bb0390]. Although it is unknown whether AR and KLF5 form a complex, some molecules including Smad3 and p300 have been demonstrated to physically interact with both AR [@bb0395], [@bb0400] and KLF5 [@bb0235]. It is worth testing whether and how KLF5 cooperates with CREB1, Sp1, Myc, ER, and AR in gene regulation in epithelial homeostasis.

In summary, we examined the effects of *Klf5* deletion on *Pten* deletion--initiated prostatic tumorigenesis in genetically modified mice and found that *Klf5* deletion promoted the development and increased the severity of *Pten* deletion--induced mPIN and prostate tumor. Interestingly, *Klf5* deletion increased the ratio of Ck18-positive luminal tumor cells to Ck5-positive basal tumor cells in tumors, suggesting a restricted promoting effect of *Klf5* deletion on luminal tumor cells. *Klf5* deletion in *Pten*-null prostate tumors increased the cell proliferation rate, which involved multiple signaling pathways including the up-regulation of growth factor EGF, activation of PI3K/AKT and MAPK, and the inactivation of the p15 cell cycle inhibitor. Further pathway analysis suggests that KLF5 cooperates with other transcription factors including CREB1, Sp1, Myc, ER, and AR to regulate gene expression in the prostate. These findings validate the tumor suppressor function of KLF5 in genetically modified mice and also provide a mouse model that shares two common genetic alterations with human prostate cancer, deletions of *PTEN* and *KLF5*.

The following are the supplementary data related to this article.Table S1Primer Sequences Used in This StudyTable S2Differentially Expressed Genes between Klf5 Wild-Type and Klf5-Null Mouse DPs in the Pten-Null Background, as Identified by Microarray Analysis. Fold Change Was the Mean Value of Four Pairs of SamplesTable S3Genes Upregulated or Downregulated by Klf5 Deletion in More than One Type of Tissue. Up-regulation in a Tissue Is Indicated by "Up" or a Positive Fold Change Number, while Down-Regulation Is Indicated by "Down" or a Negative Fold Change Number. Data for Cornea, Villus, and Bladder Were from Published Studies [@bb0205], [@bb0175], [@bb0165]Table S4Genes Dysregulated by Both *Klf5* Deletion in Pten-Null Mouse Prostates and Ectopic Expression of KLF5 or Its Acetylation-Deficient Mutant K369R in Xenograft Tumors of the DU 145 Human Prostate Cancer Cell Line (DU 145-KLF5 or DU 145-K369R). Data for DU 145 Xenografts Were from a Previous Study [@bb0120]Table S5Differentially Expressed Genes that Were Prostate Cancer Related, as Identified by the MetaCore Program, and Had Appeared in at Least One PubMed Publication on Prostate Cancer. Fold Change between *Klf5* Wild-Type and *Klf5*-Null Groups and the Number of PubMed Publications Available Are Also Shown for Each of the Genes. Positive (P) or Negative (N) Refers to a Gene's Association with the Development or Progression of Prostate Cancer Based on PubMed Publications, with P Indicating a Gene's Promoting Role in Prostate Tumorigenesis or Up-Regulation in Prostate Tumors and N indicating the Opposite. N/A, Information Is Not ClearTable S6Functional Processes Enriched by MetaCore Analysis Based on the Differentially Expressed Genes between *Klf5* Wild-Type and *Klf5*-Null Mouse DPs. Different Processes with the Same Function Are Grouped Together and Ranked Based on *P* Values (from Low to High, *P* Value \< .01). Genes Contributing to a Process Are ListedTable S7Significant Pathways Identified by the MetaCore Analysis Based on the Differentially Expressed Genes between *Klf5* Wild-Type and *Klf5*-Null Mouse DPs. All Pathways Are Ranked Based on Their *P* Values (from Low to High, *P* Value \< .01)Table S8Key Transcription Factors Significantly Associated with Differentially Expressed Genes between *Klf5* Wild-Type and *Klf5*-Null Mouse DPs, as Defined by MetaCore's Interactome Analysis for Transcription Factors. Related Biologic Processes Are Also Shown. The Ranking Is Based on *P* Values. Total Nodes Refer to All Nodes in a Transcription Factor Network, while Seed Nodes Refer to the Genes Differentially Expressed between the Experimental GroupsFigure S1Confirmation of *Klf5* deletion in mouse prostates with *Pten* hemizygous knockout. Klf5 protein was detected by IHC staining in 12-month-old APs with indicated *Klf5* deletion status; + and − indicate wild-type and deleted *Klf5* alleles, respectively.Figure S2Heat map illustrating gene expression changes caused by *Klf5* deletion in *Pten*-null prostate tumors and associated with prostate cancer in the literature. A total of 173 differentially expressed genes with \> 1.5-fold expression change and literature-based prostate cancer association was used in the heat map drawing. Each lane represents one pair of wild-type and *Klf5*-null DPs at 6 months old. Clustering in the heat map is based on the relation of genes with prostate cancer, with those reported to promote prostate cancer or be upregulated in prostate cancer as "positive", and those reported to inhibit prostate cancer or be downregulated in prostate cancer as "negative". The percentages of upregulated or downregulated genes in each group are shown. The number in the parentheses after each gene name indicates the number of publications on that gene in prostate cancer. Heat map colors reflect normalized log~2~ fold-change values of the ratio in each pair.Figure S3Molecular networks constructed for differentially expressed genes between *Klf5* knockout and wild-type by the network analysis algorithm in the MetaCore platform. The 25 networks that had more than four seed nodes with *P* \< .05 are shown. Different shapes of the nodes represent functional classifications of genes. Red and blue in the nodes indicate up-regulation and down-regulation, respectively, of genes. Lines between every two nodes indicate their interactions, with red for inhibition, green for activation, and gray for unspecified interaction. Arrow indicates the direction of a regulation. Colored thicker lines mark canonical pathways.Figure S4*Klf5* deletion upregulates p-mTor in *Pten*-null mouse prostate tumors. IHC staining was used to detect p-mTor in tissue sections of APs and DPs at 6 months of age. Deletion status of *Klf5* is indicated at the top. + and − indicate the presence and absence, respectively, of a *Klf5* or *Pten* allele.Figure S5*Klf5* deletion has no effect on apoptosis in *Pten*-null mouse prostate tumors. Apoptotic cells (indicated by arrows) were detected by the TUNEL assay in 6-month-old prostates. Deletion status of *Klf5* is indicated at the left and that of *Pten* indicated at the top. The ratio (%) of apoptotic to total cells for each group is shown at the lower left corner of each image. + and − indicate the presence and absence, respectively, of a *Klf5* or *Pten* allele. No statistical significance was detected between *Klf5*^+/+^ and *Klf5*^−/−^.
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